State of Wisconsin Investment Board purchased a new stake in shares of TESARO, Inc. (NASDAQ:TSRO) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 55,780 shares of the biopharmaceutical company’s stock, valued at approximately $7,801,000. State of Wisconsin Investment Board owned 0.10% of TESARO at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in TSRO. Vident Investment Advisory LLC purchased a new position in shares of TESARO during the first quarter valued at about $351,000. Meeder Asset Management Inc. bought a new position in shares of TESARO during the first quarter worth $177,000. Fox Run Management L.L.C. bought a new position in shares of TESARO during the second quarter worth $224,000. World Asset Management Inc bought a new position in shares of TESARO during the second quarter worth $227,000. Finally, Private Capital Advisors Inc. bought a new position in shares of TESARO during the second quarter worth $232,000.

Shares of TESARO, Inc. (NASDAQ TSRO) opened at 126.37 on Monday. The firm’s market cap is $6.85 billion. TESARO, Inc. has a 52-week low of $83.26 and a 52-week high of $192.94. The company’s 50 day moving average is $123.96 and its 200 day moving average is $146.46.

TESARO (NASDAQ:TSRO) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.52) by $0.30. The company had revenue of $29.50 million for the quarter, compared to the consensus estimate of $18.61 million. TESARO had a negative net margin of 1,301.19% and a negative return on equity of 104.00%. The company’s quarterly revenue was down 17.6% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.28) EPS. Analysts anticipate that TESARO, Inc. will post ($8.67) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This piece was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/28/state-of-wisconsin-investment-board-invests-7-80-million-in-tesaro-inc-tsro.html.

Several brokerages have commented on TSRO. Janney Montgomery Scott set a $139.00 price target on shares of TESARO and gave the stock a “hold” rating in a research report on Saturday, June 10th. Cowen and Company set a $145.00 target price on shares of TESARO and gave the company a “hold” rating in a report on Saturday, June 10th. Jefferies Group LLC set a $124.00 price target on shares of TESARO and gave the company a “hold” rating in a research note on Thursday, August 17th. Credit Suisse Group set a $190.00 price target on shares of TESARO and gave the company a “buy” rating in a research note on Friday, August 18th. Finally, Robert W. Baird reiterated a “neutral” rating on shares of TESARO in a research note on Tuesday, June 6th. One research analyst has rated the stock with a sell rating, ten have given a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $175.52.

In other news, VP Edward C. English sold 8,500 shares of TESARO stock in a transaction that occurred on Tuesday, June 6th. The shares were sold at an average price of $138.65, for a total transaction of $1,178,525.00. Following the sale, the vice president now owns 5,396 shares in the company, valued at $748,155.40. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 34.60% of the company’s stock.

TESARO Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Institutional Ownership by Quarter for TESARO (NASDAQ:TSRO)

Receive News & Stock Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related stocks with our FREE daily email newsletter.